Randomized Controlled Trial
Copyright ©The Author(s) 2022.
World J Gastroenterol. Nov 28, 2022; 28(44): 6294-6309
Published online Nov 28, 2022. doi: 10.3748/wjg.v28.i44.6294
Table 3 Change in gastroesophageal reflux disease-health related quality of life score from baseline at weeks 4 and 8 (per protocol set)
GERD-HRQLFexuprazan 40 mg
Esomeprazole 40 mg
Baseline (n = 107)
Week 4 (n = 102)
Week 8 (n = 106)
Baseline (n = 111)
Week 4 (n = 104)
Week 8 (n = 111)
mean ± SD11.88 ± 8.114.21 ± 6.174.01 ± 6.2012.98 ± 9.623.42 ± 5.043.32 ± 5.54
Change from baseline (mean ± SD)--7.71 ± 8.37-7.90 ± 8.56--9.84 ± 8.70-9.67 ± 8.56
P value1-< 0.001w< 0.001t-< 0.001w< 0.001w
LS mean difference from esomeprazole-1.061.05---
P value2-0.1370.151---

  • Citation: Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol 2022; 28(44): 6294-6309
  • URL: https://www.wjgnet.com/1007-9327/full/v28/i44/6294.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v28.i44.6294